Your browser doesn't support javascript.
loading
Discovery of substituted biphenyl imidazoles as potent, bioavailable bombesin receptor subtype-3 agonists.
He, Shuwen; Dobbelaar, Peter H; Liu, Jian; Jian, Tianying; Sebhat, Iyassu K; Lin, Linus S; Goodman, Allan; Guo, Cheng; Guzzo, Peter R; Hadden, Mark; Henderson, Alan J; Ruenz, Megan; Sargent, Bruce J; Yet, Larry; Kelly, Theresa M; Palyha, Oksana; Kan, Yanqing; Pan, Jie; Chen, Howard; Marsh, Donald J; Shearman, Lauren P; Strack, Alison M; Metzger, Joseph M; Feighner, Scott D; Tan, Carina; Howard, Andrew D; Tamvakopoulos, Constantin; Peng, Qianping; Guan, Xiao-Ming; Reitman, Marc L; Patchett, Arthur A; Wyvratt, Matthew J; Nargund, Ravi P.
Affiliation
  • He S; Department of Medicinal Chemistry, Merck Research Laboratories, Rahway, NJ 07065, USA. shuwen_he@merck.com
Bioorg Med Chem Lett ; 20(6): 1913-7, 2010 Mar 15.
Article in En | MEDLINE | ID: mdl-20167483
ABSTRACT
We report SAR studies on a novel non-peptidic bombesin receptor subtype-3 (BRS-3) agonist lead series derived from high-throughput screening hit RY-337. This effort led to the discovery of compound 22e with significantly improved potency at both rodent and human BRS-3.
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Receptors, Bombesin / Drug Discovery / Imidazoles Limits: Animals / Humans Language: En Year: 2010 Type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Receptors, Bombesin / Drug Discovery / Imidazoles Limits: Animals / Humans Language: En Year: 2010 Type: Article